Skip to main content
Premium Trial:

Request an Annual Quote

With 2.5M Euros in Funding, EU Consortium Sets Eyes on Finding Genomic Cure for Liver Cancer

NEW YORK, Feb. 23 (GenomeWeb News) - PONT (Parallel Optimization of New Technologies for Post-Genomics Drug Discovery), a research project piloted by British, Austrian, and German biotech companies and academic researchers, will be using 2.5 million in European Union grant money to find genome targets in liver cancer, project leaders said yesterday.

PONT representatives said they will rely on a strategy of parallel pre-clinical drug development, rather than sequential, to lessen the time it takes to bring a drug to trial. Other areas they are concentrating on are human tissue resources, RNA technology, and structural proteomics.

PONT received the funding in May 2004 from the EU's 6th Framework Program. The consortium is led by Graz, Austria-based Oridis Biomed; the Medical University of Graz' Institute of Pathology;  Berlin-based PSF Biotech; the Free University of Berlin's Institute of Crystallography; Munich, Germany-based Nascacell IP; and the Bude, UK-based Tripos Receptor Research.

The Scan

Highly Similar

Researchers have uncovered bat viruses that are highly similar to SARS-CoV-2, according to Nature News.

Gain of Oversight

According to the Wall Street Journal, the Biden Administration is considering greater oversight of gain-of-function research.

Lasker for mRNA Vaccine Work

The Scientist reports that researchers whose work enabled the development of mRNA-based vaccines are among this year's Lasker Award winners

PLOS Papers on Causal Variant Mapping, Ancient Salmonella, ALK Fusion Test for NSCLC

In PLOS this week: MsCAVIAR approach to map causal variants, analysis of ancient Salmonella, and more.